Show simple item record

dc.contributor.authorAhmadi, Zainab
dc.contributor.authorBernelid, Eva
dc.contributor.authorCurrow, David Christopher
dc.contributor.authorEkstrom, Magnus
dc.date.accessioned2016-11-23T04:54:46Z
dc.date.available2016-11-23T04:54:46Z
dc.date.issued2016-10-21
dc.identifier.citationAhmadi, Z., Bernelid, E., Currow, D., & Ekström, M. (2016, October). Prescription of opioids for breathlessness in end-stage COPD: a national population-based study. International Journal of Chronic Obstructive Pulmonary Disease. Dove Medical Press Ltd. https://doi.org/10.2147/copd.s112484en
dc.identifier.issn2651-2657
dc.identifier.urihttp://hdl.handle.net/2328/36752
dc.descriptionThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).en
dc.description.abstractBackground: Low-dose opioids can relieve breathlessness but may be underused in late-stage COPD due to fear of complications, contributing to poor symptom control. Objectives: We aimed to study the period prevalence and indications of opioids actually prescribed in people with end-stage COPD. Methods: The study was a longitudinal, population-based study of patients starting long-term oxygen therapy (LTOT) for COPD between October 1, 2005 and June 30, 2009 in Sweden. A random sample (n=2,000) of their dispensed opioid prescriptions was obtained from the national Prescribed Drugs Register from 91 days before starting LTOT until the first of LTOT withdrawal, death, or study end (December 31, 2009). We analyzed medication type, dispensed quantity, date of dispensing, and indications categorized as pain, breathlessness, other, or unknown. Results: In total, 2,249 COPD patients (59% women) were included. During a median follow-up of 1.1 (interquartile range 0.6–2.0) years, 1,034 patients (46%) were dispensed $1 opioid prescription (N=13,722 prescriptions). The most frequently prescribed opioids were tramadol (23%), oxycodone (23%), morphine (16%), and codeine (16%). Average dispensed quantity was 9.3 (interquartile range 3.7–16.7) defined daily doses per prescription. In the random sample, the most commonly stated indication was pain (97%), with only 2% for breathlessness and 1% for other reasons. Conclusion: Despite evidence that supported the use of opioids for the relief of breathlessness predating this study, opioids are rarely prescribed to relieve breathlessness in oxygen-dependent COPD, potentially contributing to less-than-optimal symptom control. This study creates a baseline against which to compare future changes in morphine prescribing in this setting.en
dc.language.isoen
dc.publisherDove Medical Press Limited.en
dc.rights© 2016 Ahmadi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).en
dc.subjectCOPD
dc.subjectsymptoms
dc.subjectbreathlessness
dc.subjectopioids
dc.subjectprescriptions
dc.subjectLTOT
dc.titlePrescription of opioids for breathlessness in end-stage COPD: a national population-based studyen
dc.typeArticleen
dc.identifier.doihttps://doi.org/10.2147/COPD.S112484en
dc.rights.holderThe authorsen
dc.rights.licenseCC-BY-NC


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record